The National Minority Quality Forum’s (NMQF) proposed trial eMeasure (#2764), “Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy," received more than 40 comments during the National Quality Forum’s public and member comment period for their Cardiovascular Measures 2015 project that closed on November 23, 2015 (see NMQF's response here). The overwhelming majority of the comments voiced strong support for the September 9 decision of the NQF Cardiovascular Measures Standing Committee to approve NMQF’s trial measure, and to enable Measure #2764 to advance to the next stage of voting and to complete required testing of validity and reliability.
